ATG-022
01 May 2023
ATG-022
NCT05718895
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
Antengene Corporation (Antengene Biologics Limited )
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | - |
Anticipated Start Date | 2023-02-01 |
Anticipated End Date | 2026-06-30 |
Hospital | Cancer Research SA |
---|---|
Clinical Trial Coordinator | Kelly Mead/Kate Penta |
Meggan.ORiley@socru.org.au | |
Phone | 08 8359 2565 |
Principal Investigator | Sarwan Bishnoi |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs